PAVmed Amends Lucid Diagnostics Stake, Ownership Update Filed

TL;DR

**PAVmed just updated its ownership stake in Lucid Diagnostics, watch for potential strategic moves!**

AI Summary

PAVmed Inc. filed an amended Schedule 13D/A on February 2, 2024, indicating a change in its beneficial ownership of Lucid Diagnostics Inc. common stock, effective January 26, 2024. This filing, an amendment to a previous Schedule 13D, updates the disclosures regarding PAVmed's stake in Lucid Diagnostics. This matters to investors because PAVmed is a significant shareholder and the parent company of Lucid Diagnostics, so any changes in its ownership or intentions could signal future strategic moves or impact investor confidence in Lucid Diagnostics' stock.

Why It Matters

This filing updates the public record on PAVmed's ownership in Lucid Diagnostics, which can influence market perception and potentially signal future corporate actions or strategic shifts.

Risk Assessment

Risk Level: medium — Changes in significant shareholder ownership can introduce uncertainty regarding future company direction or potential stock sales, creating medium risk for investors.

Analyst Insight

Investors should review the full amended filing to understand the specific changes in PAVmed's beneficial ownership of Lucid Diagnostics, as this could impact future strategic decisions or market sentiment for Lucid Diagnostics stock.

Key Players & Entities

• Lucid Diagnostics Inc. (company) — Subject Company (Issuer) of the common stock
• PAVmed Inc. (company) — Filing Person (Reporting Person) and parent company of Lucid Diagnostics Inc.
• Lishan Aklog, M.D. (person) — Chairman and Chief Executive Officer of PAVmed Inc., authorized to receive notices
• $0.001 (dollar_amount) — par value per share of Lucid Diagnostics Inc. Common Stock
• January 26, 2024 (date) — Date of event requiring the filing of this statement
• February 2, 2024 (date) — Filing date of the SC 13D/A

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $1.31 — he Common Stock at an exercise price of $1.31 per share, with each such stock option
• $4,675,256 — ng Person elected to receive payment of $4,675,256 of fees and reimbursements accrued unde

Filing Documents

• formsc13da.htm (SC 13D/A) — 57KB
• 0001493152-24-004790.txt ( ) — 59KB

of this Schedule 13D, which information is incorporated herein by reference

Item 4 of this Schedule 13D, which information is incorporated herein by reference. Item 4. Purpose of the Transaction On January 31, 2023, the Issuer granted to each of Mr. Lapidus, Dr. Cox, Dr. Sokolov, Mr. Sparks and Ms. White a stock option to purchase 175,000 shares of the Common Stock at an exercise price of $1.31 per share, with each such stock option grant vesting: (i) one-third on December 31, 2023; and (ii) the remaining vesting ratably on a quarterly basis commencing March 31, 2024 with a final quarterly vesting date of December 31, 2025. As previously disclosed, the Reporting Person and the Issuer (which is a majority owned subsidiary of the Reporting Person) are parties to a management services agreement (as amended to date, the “ MSA ”) and a payroll and benefit expense reimbursement agreement (the “ PBERA ”). Pursuant to these agreements, the Reporting Person provides management and oversight of certain of the Issuer’s activities, makes certain resources available to the Issuer, and pays certain payroll and benefit-related expenses in respect of the Issuer’s personnel on behalf of the Issuer. The Reporting Person may elect to receive payment of fees and reimbursement of expenses under such agreements in shares of Common Stock, subject to the terms of such agreements (including, in the case of the PBERA, Person elected to receive payment of $4,675,256 of fees and reimbursements accrued under the MSA and the PBERA during the period from October 1, 2022 through December 31, 2022, through the issuance of 3,331,771 shares of Common Stock. The Reporting Person is the parent company of the Issuer and, with its ownership of approximately 72.2% of the outstanding shares of Common Stock, has the power to elect all of the directors of the Issuer and to control all matters that wou

above

Item 4 above. (d) Not applicable. (e) Not applicable.

Signatures

Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. PAVMED INC. Dated: February 2, 2024 By: /s/ Lishan Aklog Lishan Aklog, M.D. Chief Executive Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR